{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-006267","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.432286+00:00","generated_at":"2026-06-18T23:08:42.998125+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Enveric Biosciences appoints Kevin Coveney as CFO effective March 13, 2023; interim CFO Robert Dickey IV resigns","bullets":["Kevin Coveney appointed CFO effective March 13, 2023, succeeding interim CFO Robert Dickey IV.","Coveney receives $385,000 base salary, bonus up to 40% of base, and 26,500 RSUs vesting over 4 years.","Coveney brings 30+ years biotech finance experience; previously CFO at Memgen and Q-State Biosciences.","Interim CFO Robert Dickey IV resigns; resignation not due to any disagreement with company.","Inducement RSU grant approved by board under NASDAQ Listing Rule 5635(c)(4)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-006267","json":"https://secwatch.observer/filing/0001493152-23-006267.json","markdown":"https://secwatch.observer/filing/0001493152-23-006267.md","text":"https://secwatch.observer/filing/0001493152-23-006267.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315223006267/0001493152-23-006267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315223006267/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:08:42.998125+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f3bd8895d","claim":"Kevin M. Coveney was appointed as chief financial officer at Enveric Biosciences, Inc..","evidence_excerpt":"On February 22, 2023, Kevin M. Coveney, 59, was appointed as the chief financial officer of Enveric Biosciences, Inc. (the “Company”) effective March 13, 2023 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223006267/0001493152-23-006267-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"chief financial officer"}],"fact_type":"executive_change"},{"claim_id":"94b2c9cec8","claim":"Robert Dickey IV departed as chief financial officer at Enveric Biosciences, Inc..","evidence_excerpt":"Effective as of the Effective Date, Robert Dickey IV will resign from his position as the Company’s chief financial officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223006267/0001493152-23-006267-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resign"},{"label":"Role","value":"chief financial officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}